Tyche Wealth Partners LLC Buys Shares of 12,061 Abbott Laboratories (NYSE:ABT)

Tyche Wealth Partners LLC bought a new stake in shares of Abbott Laboratories (NYSE:ABT) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 12,061 shares of the healthcare product maker’s stock, valued at approximately $1,328,000.

Several other large investors have also recently bought and sold shares of the stock. Altshuler Shaham Ltd acquired a new position in shares of Abbott Laboratories in the 4th quarter worth approximately $28,000. Cornerstone Planning Group LLC acquired a new position in shares of Abbott Laboratories in the 2nd quarter worth approximately $28,000. FWL Investment Management LLC acquired a new position in shares of Abbott Laboratories in the 4th quarter worth approximately $33,000. True Wealth Design LLC acquired a new position in shares of Abbott Laboratories in the 4th quarter worth approximately $33,000. Finally, Quarry LP grew its stake in shares of Abbott Laboratories by 132.9% in the 2nd quarter. Quarry LP now owns 333 shares of the healthcare product maker’s stock worth $36,000 after purchasing an additional 190 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In other news, VP John A. Jr. Mccoy sold 472 shares of Abbott Laboratories stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $118.50, for a total value of $55,932.00. Following the transaction, the vice president now owns 18,760 shares of the company’s stock, valued at $2,223,060. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, EVP Daniel Gesua Sive Salvadori sold 963 shares of Abbott Laboratories stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $118.50, for a total value of $114,115.50. Following the transaction, the executive vice president now owns 125,697 shares of the company’s stock, valued at $14,895,094.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP John A. Jr. Mccoy sold 472 shares of Abbott Laboratories stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $118.50, for a total transaction of $55,932.00. Following the completion of the transaction, the vice president now directly owns 18,760 shares in the company, valued at approximately $2,223,060. The disclosure for this sale can be found here. Insiders sold 56,435 shares of company stock worth $6,451,298 over the last ninety days. 0.47% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

ABT has been the topic of several recent research reports. Evercore ISI lifted their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Royal Bank of Canada reiterated an “outperform” rating and issued a $128.00 target price on shares of Abbott Laboratories in a report on Wednesday, February 14th. TheStreet upgraded shares of Abbott Laboratories from a “c+” rating to a “b-” rating in a report on Thursday, December 21st. Raymond James raised their target price on shares of Abbott Laboratories from $124.00 to $127.00 and gave the stock an “outperform” rating in a report on Thursday, January 25th. Finally, Barclays raised their target price on shares of Abbott Laboratories from $133.00 to $141.00 and gave the stock an “overweight” rating in a report on Friday, January 26th. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $122.14.

Abbott Laboratories Stock Up 0.3 %

NYSE ABT traded up $0.31 during trading on Tuesday, reaching $109.20. The company’s stock had a trading volume of 7,279,806 shares, compared to its average volume of 5,590,588. The company has a current ratio of 1.64, a quick ratio of 1.16 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $189.48 billion, a PE ratio of 33.40, a PEG ratio of 2.63 and a beta of 0.74. The business has a 50-day moving average price of $114.67 and a 200-day moving average price of $107.51. Abbott Laboratories has a 1-year low of $89.67 and a 1-year high of $121.64.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, January 24th. The healthcare product maker reported $1.19 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.19. The firm had revenue of $10.24 billion during the quarter, compared to analysts’ expectations of $10.19 billion. Abbott Laboratories had a net margin of 14.27% and a return on equity of 20.65%. The company’s revenue was up 1.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.03 earnings per share. On average, research analysts forecast that Abbott Laboratories will post 4.62 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 2.01%. The ex-dividend date is Friday, April 12th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.48%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.